<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03507452</url>
  </required_header>
  <id_info>
    <org_study_id>18795</org_study_id>
    <secondary_id>2017-004052-29</secondary_id>
    <nct_id>NCT03507452</nct_id>
  </id_info>
  <brief_title>First-in-human Study of BAY2287411 Injection, a Thorium-227 Labeled Antibody-chelator Conjugate, in Patients With Tumors Known to Express Mesothelin</brief_title>
  <official_title>An Open-label, First-in-human, Multi-center Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of a Thorium-227 Labeled Antibody-chelator Conjugate, BAY2287411 Injection, in Patients With Solid Tumors Known to Express Mesothelin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate, in patients with tumors known to express the&#xD;
      protein mesothelin, the following properties of BAY2287411 injection:&#xD;
&#xD;
        -  safety (to identify, assess, minimize, and appropriately manage the risks associated to&#xD;
           the study drug)&#xD;
&#xD;
        -  tolerability (the degree to which side effects can be tolerated by your body)&#xD;
&#xD;
        -  maximum tolerated dose&#xD;
&#xD;
        -  pharmacokinetics (the effect of your body on the study drug)&#xD;
&#xD;
        -  anti-tumor activity&#xD;
&#xD;
        -  recommended dose for further clinical development&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 13, 2018</start_date>
  <completion_date type="Anticipated">March 21, 2022</completion_date>
  <primary_completion_date type="Actual">September 29, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of DLTs (dose-limiting toxicity)</measure>
    <time_frame>6 weeks (42 days)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The incidence of treatment-emergent adverse events (TEAEs), drug-related adverse events (AEs), and serious adverse events (SAEs)</measure>
    <time_frame>6 months after the end of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax of Thorium-227 after single dose of Cycle 1</measure>
    <time_frame>From Day 1 to 43</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax of Radium-223 after single dose of Cycle 1</measure>
    <time_frame>From Day 1 to 43</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax of Total antibody after single dose of Cycle 1</measure>
    <time_frame>From Day 1 to 43</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC(0-42 days) of Radium-223 after single dose of Cycle 1</measure>
    <time_frame>From Day 1 to 43</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC(0-42 days) of Total antibody after single dose of Cycle 1</measure>
    <time_frame>From Day 1 to 43</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC(0-42 days) of Thorium-227 after single dose of Cycle 1</measure>
    <time_frame>From Day 1 to 43</time_frame>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Advanced Recurrent Epithelioid Mesothelioma</condition>
  <condition>Serous Ovarian Cancer</condition>
  <condition>Metastatic or Locally Advanced Pancreatic Ductal Adenocarcinoma (Optional, Dose Expansion)</condition>
  <arm_group>
    <arm_group_label>Dose escalation cohort a</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with either advanced recurrent epithelioid mesothelioma or serous ovarian cancer who have exhausted available therapeutic options.&#xD;
The dose of Thorium-227 will start at 1.5 MBq and increase in steps of 1.0 or 1.5 MBq, with antibody doses of 10 mg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose escalation cohort b</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with either advanced recurrent epithelioid mesothelioma or serous ovarian cancer who have exhausted available therapeutic options.&#xD;
The dose of Thorium-227 will start at 1.5 MBq and increase in steps of 1.0 or 1.5 MBq, with a total antibody dose within the range of 10 - 50 mg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Expansion Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with advanced recurrent epithelioid mesothelioma or serous ovarian cancer, who have exhausted available therapeutic options&#xD;
Dose / Regimen 1 (to be determined after completion of the dose escalation)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Expansion Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with advanced recurrent epithelioid mesothelioma or serous ovarian cancer, who have exhausted available therapeutic options&#xD;
Dose / Regimen 2 (to be determined after completion of the dose escalation)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose expansion Cohort 3 (optional)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with histologically or cytologically confirmed unresectable, metastatic or locally advanced pancreatic ductal adenocarcinoma&#xD;
Dose / Regimen to be determined</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose escalation cohort c</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with either advanced recurrent epithelioid mesothelioma or serous ovarian cancer who have exhausted available therapeutic options.&#xD;
The dose of Thorium-227 will start at 1.5 MBq and increase in steps of 1.0 or 1.5 MBq, with antibody doses of 10 - 150 mg mg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose escalation cohort d</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with either advanced recurrent epithelioid mesothelioma or serous ovarian cancer who have exhausted available therapeutic options.&#xD;
The dose of Thorium-227 will start at 1.5 MBq and increase in steps of 1.0 or 1.5 MBq, with antibody doses of 10 - 400 mg.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BAY2287411</intervention_name>
    <description>Dose Escalation part:&#xD;
A single dose will be administered intravenously on Day 1 of each cycle lasting 6 weeks (42 days).</description>
    <arm_group_label>Dose escalation cohort a</arm_group_label>
    <arm_group_label>Dose escalation cohort b</arm_group_label>
    <arm_group_label>Dose escalation cohort c</arm_group_label>
    <arm_group_label>Dose escalation cohort d</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BAY2287411</intervention_name>
    <description>Dose Expansion part:&#xD;
The selection of the dose level(s) /regimen(s) to be evaluated will be based on the overall benefit / risk and PK profile observed in the dose escalation.</description>
    <arm_group_label>Dose Expansion Cohort 1</arm_group_label>
    <arm_group_label>Dose Expansion Cohort 2</arm_group_label>
    <arm_group_label>Dose expansion Cohort 3 (optional)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
          -  Male or female subjects ≥ 18 years of age&#xD;
&#xD;
          -  ECOG PS (Eastern Cooperative Oncology Group Performance Status) of 0 or 1&#xD;
&#xD;
          -  Patients with advanced malignant epithelioid mesothelioma or advanced recurrent serous&#xD;
             ovarian cancer, who have exhausted available therapeutic options; in addition, in the&#xD;
             dose expansion part of the study, patients with metastatic pancreatic adenocarcinoma,&#xD;
             who have exhausted available therapeutic options&#xD;
&#xD;
          -  Availability of fresh or archival tumor tissue samples&#xD;
&#xD;
          -  Adequate bone marrow, liver and renal function, as assessed by pre-defined laboratory&#xD;
             requirements (within 28 days before start of study drug treatment)&#xD;
&#xD;
          -  A negative serum pregnancy test in women of childbearing potential (WOCBP) performed&#xD;
             within 7 days before the start of study drug administration. Women and men of&#xD;
             reproductive potential must agree to use highly effective methods of contraception,&#xD;
             when sexually active.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Impaired cardiac function, clinically significant cardiac disease or cardiac&#xD;
             arrhythmias&#xD;
&#xD;
          -  Pericarditis (any CTCAE grade) or pericardial effusion (CTCAE Grade ≥ 2)&#xD;
&#xD;
          -  Left Ventricular Ejection Fraction (LVEF) &lt; 50% (as measured at screening by&#xD;
             echocardiogram).&#xD;
&#xD;
          -  History of anaphylactic reactions to monoclonal antibody therapy&#xD;
&#xD;
          -  History of Myelodysplastic syndrome (MDS)/treatment-related acute myeloid leukemia&#xD;
             (t-AML) or with features suggestive of MDS/AML&#xD;
&#xD;
          -  Infections of CTCAE (Common Terminology Criteria for Adverse Events) version 5.0 Grade&#xD;
             2 not responding to therapy or active clinically serious infections of CTCAE Grade &gt;2;&#xD;
             known human immunodeficiency virus (HIV) infection; active hepatitis B virus (HBV) or&#xD;
             hepatitis C virus (HCV)infection requiring treatment. Patients with chronic HBV or HCV&#xD;
             infection are eligible at the investigator's discretion provided that the disease is&#xD;
             stable and sufficiently controlled under treatment&#xD;
&#xD;
          -  Known brain, spinal or meningeal metastases&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Cancer Institute</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HUS, Meilahden sairaala</name>
      <address>
        <city>Helsinki</city>
        <zip>00290</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nederlands Kanker Instituut</name>
      <address>
        <city>Amsterdam</city>
        <zip>1066 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitair Medisch Centrum Groningen</name>
      <address>
        <city>Groningen</city>
        <zip>9713 GZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Skånes Universitetssjukhus</name>
      <address>
        <city>Lund</city>
        <zip>221 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Marsden NHS Trust (Surrey)</name>
      <address>
        <city>Sutton</city>
        <state>Surrey</state>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
    <country>Netherlands</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>April 16, 2018</study_first_submitted>
  <study_first_submitted_qc>April 16, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 25, 2018</study_first_posted>
  <last_update_submitted>November 11, 2021</last_update_submitted>
  <last_update_submitted_qc>November 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Malignant Mesothelioma</keyword>
  <keyword>Malignant Pleural Epithelioid Mesothelioma</keyword>
  <keyword>Malignant Peritoneal Epithelioid Mesothelioma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mesothelioma</mesh_term>
    <mesh_term>Mesothelioma, Malignant</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>BAY 2287411</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

